13F Holdings
中文EN

ATHE ALTERITY THERAPEUTICS LTD IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1131343 · Reporting currency AUD · Fiscal year ends 06/30

Financial factors as of 2018-06-30 (FY2018), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY51.9%
TTM net income YoY-9.6%
TTM EPS YoY-9.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin-4,108.8%
FCF margin-3,135.4%
EBITDA margin—

Returns

ROE-41.6%
ROA-37.6%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets14.1%
Debt / equity0.00x
Current ratio7.06x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue31.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: AUD FY2025*2025-06-30FY2024*2024-06-30FY20232023-06-30FY20222022-06-30FY20212021-06-30
Income statement
Revenue—————
R&D expense14.40M18.64M13.20M14.75M12.28M
SG&A expense5.48M4.76M5.06M5.51M6.94M
Interest expense6,1887,2174,5652,2851,299
Pretax income-12.08M-19.08M-13.70M-12.78M-15.31M
Income tax68,05546,088104,45970,008—
Net income-12.15M-19.12M13.81M12.85M15.31M
EPS (basic)-0.19-0.52-0.57-0.53-0.90
EPS (diluted)-0.19-0.52-0.57-0.53-0.90
Weighted avg. shares (diluted)6.40B3.65B2.43B2.41B1.70B
Balance sheet
Cash & equivalents33.16M12.64M15.77M34.81M28.12M
Receivables3.94M4.04M8.67M4.73M4.28M
Current assets45.87M19.04M27.05M41.14M33.49M
PP&E, netmay include right-of-use assets (IFRS)3,84832,15461,776102,55131,313
Total assets46.03M19.22M27.32M41.36M33.59M
Current liabilities3.53M5.37M4.38M5.82M3.07M
Total liabilities3.62M5.43M4.50M5.89M3.12M
Shareholders' equity-225.89M-214.16M-195.13M35.47M30.47M
Shares outstanding——2.44B2.41B2.08B
Cash flow statement
Operating cash flow-11.45M-12.61M-20.04M-12.34M-17.33M
Capital expenditure—5,7227,31189,14710,472
Free cash flow—-12.61M-20.04M-12.43M-17.34M
Investing cash flow-7.50M-5,722-36,461-89,147-10,472
Financing cash flow39.67M9.22M124,34016.30M36.69M
Stock-based compensation979,920881,950966,5711.51M1.95M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, AUD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.